These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 7620213)
1. Proceedings of the International Conference on Bioreductive Drug Activation. Lake Tahoe, California, August 16-19, 1994. Oncol Res; 1994; 6(10-11):459-559. PubMed ID: 7620213 [No Abstract] [Full Text] [Related]
2. Recent developments in the design of bioreductive drugs. Denny WA; Wilson WR; Hay MP Br J Cancer Suppl; 1996 Jul; 27():S32-8. PubMed ID: 8763842 [No Abstract] [Full Text] [Related]
3. Bioreductive prodrugs for cancer therapy. Seddon B; Kelland LR; Workman P Methods Mol Med; 2004; 90():515-42. PubMed ID: 14657582 [No Abstract] [Full Text] [Related]
4. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423 [TBL] [Abstract][Full Text] [Related]
5. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844 [TBL] [Abstract][Full Text] [Related]
6. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Workman P Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214 [TBL] [Abstract][Full Text] [Related]
7. The 8th International Conference on Chemical Modifiers of Cancer Treatment. Part 1. Proceedings. Kyoto, Japan, June 16-19, 1993. Int J Radiat Oncol Biol Phys; 1994 May; 29(2):229-412. PubMed ID: 7910815 [No Abstract] [Full Text] [Related]
8. Electrodrugs: an electrochemical prodrug activation strategy. Norman DJ; González-Fernández E; Clavadetscher J; Tucker L; Staderini M; Mount AR; Murray AF; Bradley M Chem Commun (Camb); 2018 Aug; 54(66):9242-9245. PubMed ID: 30066701 [TBL] [Abstract][Full Text] [Related]
9. Nitro reduction as an electronic switch for bioreductive drug activation. Siim BG; Denny WA; Wilson WR Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242 [TBL] [Abstract][Full Text] [Related]
10. Design of anticancer prodrugs for reductive activation. Chen Y; Hu L Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784 [TBL] [Abstract][Full Text] [Related]
12. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Lee AE; Wilson WR Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604 [TBL] [Abstract][Full Text] [Related]
13. Proceedings of the International Conference on Bone Morphogenetic Proteins. June 7-11, 2000. Lake Tahoe, California, USA. J Bone Joint Surg Am; 2001; 83-A Suppl 1(Pt 1):S1-78. PubMed ID: 11305283 [No Abstract] [Full Text] [Related]
14. International Conference on Herpetic Eye Diseases. North Lake Tahoe, California, USA, September 6-8, 1986. Proceedings. Curr Eye Res; 1987 Jan; 6(1):1-286. PubMed ID: 3829697 [No Abstract] [Full Text] [Related]
15. Enzymology of bioreductive drug activation. Ross D; Beall HD; Siegel D; Traver RD; Gustafson DL Br J Cancer Suppl; 1996 Jul; 27():S1-8. PubMed ID: 8763836 [No Abstract] [Full Text] [Related]